Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
April 24, 2024 07:00 ET
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Adeia Enters into Multi-year IP License Renewal with Altimedia
April 23, 2024 08:30 ET
|
Adeia Inc.
SAN JOSE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA), a company known for its groundbreaking innovations in entertainment experiences, has announced today that Altimedia, a...
Adeia, 미디어 플랫폼 기업인 Altimedia와 IP 라이선스 계약 다년 연장 합의
April 23, 2024 08:30 ET
|
Adeia Inc.
미국 캘리포니아주 산호세, April 23, 2024 (GLOBE NEWSWIRE) -- 엔터테인먼트 경험의 새로운 혁신을 제시하는 Adeia Inc. (아데이아) (나스닥: ADEA)는 첨단 미디어 서비스 관리 솔루션 기업인 Altimedia (알티미디어)가 Adeia의 미디어 부문 지적재산권(IP) 포트폴리오에 대한 다년 간의 라이선스 계약을...
Metasphere Labs Inc. Unveils Bitcoin-Based Identity System, and Enters Exclusive Licensing Talks with Bot Ventures Inc.
April 23, 2024 07:30 ET
|
Metasphere Labs Inc.
VANCOUVER, British Columbia, April 23, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is...
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
April 22, 2024 08:00 ET
|
Elevai Labs Inc.
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
April 22, 2024 07:30 ET
|
Lexeo Therapeutics
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN...
Adeia Enters into IP License Agreement with Magenta Telekom
April 18, 2024 08:30 ET
|
Adeia Inc.
SAN JOSE, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Adeia Inc. (Nasdaq: ADEA) ("Adeia" or the "Company"), the company whose patented innovations shape the way the world explores and experiences...
Horizon Group Inspires Creativity Through Partnerships with Top Brands
April 15, 2024 09:00 ET
|
Horizon Group USA
WARREN, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Horizon Group USA, a leading global provider of innovative activity products, continues to keep creativity fun and accessible for families by...
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024 07:00 ET
|
Arvinas Inc.
– Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the License Agreement for up to $1.01...
ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
April 10, 2024 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...